[Specific immunoglobulin and acyclovir in the prevention and treatment of varicella zoster infections in children with neoplastic diseases].
Immunocompromised children with acute leukemias and solid tumors are at high risk of fatal varicella infection. Reviewing a total of 242 patients at risk we have found that zoster immune plasma from reconvalescent patients (ZIP) and commercially available specific varicella/zoster immune globulin (VZIG) both prevent fatal disease. In addition, Acyclovir was effective against VZV-infections in this group of patients. We summarize our present policy of prophylaxis and treatment of immunocompromised children with neoplastic disease who have been exposed to VZV.
D000208:Acute Disease; D000212:Acyclovir / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006562:Herpes Zoster / Q000628:therapy*; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007938:Leukemia / Q000150:complications; D009369:Neoplasms / Q000150:complications*; D011379:Prognosis
D000212:Acyclovir
Spezifisches Immunglobulin und Acyclovir in Prophylaxe und Behandlung von Varizella-Zoster-Infektionen bei Kindern mit neoplastischen Erkrankungen.